Clinical Trial Update: An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836. [Phase 1]

View source ↗

Summary

Phase 1 open-label, randomized study assessing the relative bioavailability of GSK2212836, with a single-dose period followed by single-blind repeat dosing, in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• GSK2212836

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cardiovascular Disease | Phase 1 | Status: COMPLETED